Who
Stuart Poulton
EVP, Chief Development Officer
Company insider
Files Form 4 as: EVP, Chief Development Officer, Karyopharm Therapeutics.
In numbers
- Trades disclosed
- 34
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $203K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Feb 2023
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,342189 at $7.10 | filing |
| 28 Jul 2026filed 30 Jul 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,342189 at $7.10 | filing |
| 14 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,829403 at $9.50 | filing |
| 14 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,829403 at $9.50 | filing |
| 13 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —896 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —896 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K5,101 at $9.41 | filing |
| 2 Mar 2026filed 3 Mar 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K5,101 at $9.41 | filing |
| 17 Feb 2026filed 19 Feb 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,262378 at $8.63 | filing |
| 17 Feb 2026filed 19 Feb 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,262378 at $8.63 | filing |
| 31 Jan 2026filed 3 Feb 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,415 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,415 at $0.00 | filing |
| 15 Oct 2025filed 16 Oct 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —39,682 at $0.00 | filing |
| 15 Sep 2025filed 16 Sep 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,578401 at $6.43 | filing |
| 12 Sep 2025filed 16 Sep 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —888 at $0.00 | filing |
| 29 Jul 2025filed 30 Jul 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $835191 at $4.37 | filing |
| 4 Mar 2025filed 6 Mar 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K3,548 at $6.29 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,166 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.